These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8239682)

  • 21. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.
    Oesterreich S; Hilsenbeck SG; Ciocca DR; Allred DC; Clark GM; Chamness GC; Osborne CK; Fuqua SA
    Clin Cancer Res; 1996 Jul; 2(7):1199-206. PubMed ID: 9816288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The value of searching for additional prognostic factors in combination with Nottingham Prognostic Index in breast carcinoma patients].
    Jakić-Razumović J; Corić M; Vrbanec D; Babić D; Hlupić L; Belev B
    Lijec Vjesn; 2005; 127(1-2):3-7. PubMed ID: 16145866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic variables in greek patients with stage II breast cancer: a Hellenic Cooperative Oncology Group study.
    Fountzilas G; Vasilaros S; Koukouras D; Malamos N; Pectasides D; Adamou A; Nenopoulou E; Kiriakou K; Zouvani I; Katsohis K; Kappas A; Skopa C; Semoglou C; Fahantidis E; Konstantaras C; Vasilaki E; Economopoulos T; Bacoyiannis H; Bafaloukos D; Razi E; Polichronis A; Androulakis G; Papaioannou T; Pavlidis N; Kosmidis P
    Anticancer Res; 1997; 17(6D):4681-9. PubMed ID: 9494589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations.
    Agoff SN; Swanson PE; Linden H; Hawes SE; Lawton TJ
    Am J Clin Pathol; 2003 Nov; 120(5):725-31. PubMed ID: 14608899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
    Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
    J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
    Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L
    J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
    Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
    Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
    Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
    Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
    Yoshida M; Saji S; Takagi H; Takeuchi S; Tsuda H; Nimura Y; Mizumoto R; Miyazaki I; Kobayashi S; Noguchi M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2325-33. PubMed ID: 8259846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
    Skasko E; Paszko Z; Mazur S
    Neoplasma; 2005; 52(1):10-7. PubMed ID: 15739020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
    Wiedswang G; Borgen E; Kåresen R; Kvalheim G; Nesland JM; Qvist H; Schlichting E; Sauer T; Janbu J; Harbitz T; Naume B
    J Clin Oncol; 2003 Sep; 21(18):3469-78. PubMed ID: 12972522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.